Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

The dose-response relationship is a cornerstone concept in pharmacology that describes how the effects of a drug correlate with the dose administered. It is crucial for understanding the therapeutic efficacy and safety of drugs, as it helps determine the most effective and safest dose for a given patient. Essentially, the dose-response relationship explores how varying drug concentrations in the body lead to changes in biological responses, from minimal effects at low doses to maximal effects at higher doses. The relationship is often depicted as a dose-response curve, where the dose of a drug is plotted on the x-axis and the resulting pharmacological effect on the y-axis. The curve typically shows an initial, gradual increase in effect as the dose rises, followed by a plateau or ceiling effect where no further increase in the therapeutic response occurs despite further increases in dose. Understanding the dose-response relationship involves several key concepts: potency, which refers to the amount of drug needed to produce a given effect; efficacy, which is the maximal effect a drug can achieve, regardless of dose; and the ED50, which is the dose at which 50% of the maximal effect is observed [1]. The relationship can be classified into graded dose-response, which applies to individual responses, and quantal dose-response, which looks at population-wide responses to a particular dose.

Methodology

The methodology of studying the dose-response relationship involves a systematic approach to understand how varying drug doses affect biological responses. This process typically follows these key steps:

Drug administration and dose selection: The first step is to administer the drug at different doses to either animal models or human subjects. In clinical trials, doses are chosen based on preclinical data, with careful attention to the expected therapeutic and toxic dose ranges. Doses are often tested incrementally to observe changes in response [2].

Data collection and measurement: The pharmacological effect is measured across a range of doses. For graded dose-response curves, the response is recorded continuously for each dose level. Common measurements include changes in physiological parameters (e.g., blood pressure, heart rate) or symptom relief (e.g., pain reduction) [3,4]. In quantal dose-response studies, the response is often binary (e.g., presence or absence of a therapeutic effect).

Analysis of the dose-response curve: The collected data is plotted on a dose-response curve, where the x-axis represents the dose of the drug, and the y-axis represents the effect observed. The curve helps identify several key parameters:

Threshold dose (the minimal dose that produces a measurable response),

Efficacy (the maximal effect),

Potency (the dose required to achieve a certain effect),

ED50 (the dose at which 50% of the maximal response occurs).

Evaluation of key parameters: Researchers analyze the curve to determine the potency and efficacy of the drug. Potency is evaluated by the dose required to produce a certain effect, while efficacy reflects the drug’s ability to reach its maximal effect [5,6].

Consideration of variables: Factors such as tolerance, patient demographics, genetics, and drug interactions are considered, as they can influence how the dose-response curve shifts.

Types of dose-response relationships

Dose-response relationships can vary depending on the nature of the drug and its effect. The two primary types of dose-response relationships are:

Graded dose-response: This type of dose-response relationship describes the effect of a drug on an individual. As the dose increases, the response gradually increases until the maximal effect is reached [7-8-9]. Most pharmacological agents exhibit a graded dose-response curve. For example, pain relief from an analgesic drug increases as the dose increases, but only up to a certain point.

Quantal Dose-response: This type of dose-response relationship describes the effect of a drug in a population, where the outcome is either present or absent (e.g., survival or death, the presence or absence of a therapeutic effect) [10]. The relationship is often used to determine the percentage of individuals who will experience a specific effect at a given dose, such as the percentage of patients who experience side effects at various doses of a drug.

Conclusion

The dose-response relationship is a cornerstone of pharmacology that allows us to understand how drugs work and how to use them effectively and safely. By studying how different doses of a drug produce varying effects, researchers and clinicians can determine the most effective treatment regimens, tailor therapy to individual needs, and minimize adverse effects. Understanding this relationship is crucial for drug development, clinical practice, and advancing personalized medicine.

1. Guimarães PO, Tricoci P (2015) Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?. Expert Opin Pharmacother 16: 1983-1995.

Indexed at, Google Scholar, Crossref

2. Westman PC, Lipinski MJ, Torguson R, Waksman R (2017) A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovasc Revasc Med 18: 79-85.

Indexed at, Google Scholar, Crossref

3. Vaidya GN, Khan A, Ghafghazi S (2019)   Effect of morphine use on oral P2Y12 platelet inhibitors in acute myocardial infarction: Meta-analysis. Indian Heart J 71: 126-135.

Indexed at, Google Scholar, Crossref

4. Roffman DS (2016) Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor. J Pharm Pract 29: 239-249.

Indexed at, Google Scholar, Crossref

5. Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, et al. (2014)  Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thromb Haemost 111: 266-672.

Indexed at, Google Scholar, Crossref

6. Kubica J, Adamski P, Ostrowska M, Koziński M, Obońska K, et al. (2015) Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials 16: 198.

Indexed at, Google Scholar, Crossref

7. De Backer O, Ratcovich H, Biasco L, Pedersen F, Helqvist S, et al.  (2015)  Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study. Thromb Haemost 114: 623-631.

Indexed at, Google Scholar, Crossref

8. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, et al. ( 2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovascular Interv 5: 797-804.

Indexed at, Google Scholar, Crossref

9. Di Vito L, Versaci F, Limbruno U, Pawlowski T, Gatto L, et al. (2016) Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. J Cardiovascular Med (Hagerstown) 17: 701-706.

Indexed at, Google Scholar, Crossref

10. Henrich A, Claussen CH, Dingemanse J, Krause A (2021) Pharmacokinetic/pharmacodynamics modeling of drug interactions at the P2Y 12 receptor between selatogrel and oral P2Y 12 antagonists.CPT Pharmacometrics Syst Pharmacol 10: 735-747.

Indexed at, Google Scholar, Crossref